IgA肾病（IgAN）是全球最常见的原发性肾小球疾病，临床表现多样，严重影响患者生活质量。近期举行的世界肾脏病大会（WCN 2025）发布了多项IgA肾病诊疗研究，公布了IgA肾病在病理生理学和药物治疗等方面的前沿进展。医脉通肾内频道特此整理IgA肾病相关亮点摘要，以飨读者。 当前，仅依靠肾功能下降的临床和组织学风险因素，无法准确识别IgAN高风险患者。基于此，国际IgA肾病预测工具（IRP-Ig ...

The following is a summary of “Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy,” published in the ...

Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353 , 883–887 (1999). Article CAS Google Scholar ...

IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 67 , 504–513 (2005). Article CAS PubMed Google Scholar ...

IgA nephropathy is an autoimmune disease of the kidneys. It’s associated with several health conditions and is a significant contributor to chronic kidney disease and kidney failure. In the ...

The following is a summary of “GPX4 expression changes in proximal tubule cells highlight the role of ferroptosis in IgAN,” published in the January 2025 issue of Scientific Reports by Qing et al.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA ...